JSPR
Jasper Therapeutics, Inc.
$0.51
+2.91%
2026-10-23
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Key Fundamentals
Forward P/E
-0.24
EPS (TTM)
$-0.93
ROE
-255.0%
Profit Margin
0.0%
Debt/Equity
19.11
Price/Book
12.18
Beta
3.04
Market Cap
$20.3M
Avg Volume (10D)
371K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$0.97
60D Low
$0.46
Avg Volume
490K
Latest Close
$0.51
Get breakout alerts for JSPR
Sign up for Breakout Scanner to receive daily notifications when JSPR triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Jasper Therapeutics, Inc. (JSPR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors JSPR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. JSPR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.